CoChat

Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients

Radaelli, M, Moiola, L, Sangalli, F, Esposito, F, Barcella, V, Ferrè, L, Rodegher, M, Colombo, B, Fazio, R, Martinelli, V, Comi, G · 2016 · Multiple Sclerosis Journal
Cited by 85

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Objective: To assess the long-term benefit-risk profile of repeated courses of rituximab in Caucasian patients affected by neuromyelitis optica (NMO) and related disorders, in everyday clinical practice. Methods: This is a prospective observational study performed at San Raffaele Hospital, Milan, Italy. From February 2006, we recruited 21 patients affected by NMO and NMO spectrum of disorders (NMOSD) whom underwent at least one cycle of intravenous (i.v.) rituximab and then were followed for at least 2 years. Results: At a mean follow-up time of 48 months, we observed a significant reduction of the annualized relapse rate (ARR), from 2.0 to 0.16 ( p < 0.01); and of the median Expanded Disability Status Scale (EDSS), from 5.5 to 4.0 ( p < 0.013). There were 12 patients (57%) who remained disease free during the follow-up period. Five patients (24%) reported mild hematological adverse events. Serious infectious adverse events were reported by another four patients: These were all wheelchair bound at the beginning of their rituximab treatment. Conclusions: A fixed treatment scheme of rituximab, with re-treatment every 6 months, was efficacious for NMO and NMOSD, with a good safety profile; however, to obtain an even better benefit-risk ratio, close monitoring of CD19 + B cells should be performed before the re-treatment of patients with high-level disability, concomitant leukopenia and hypogammaglobulinemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1352458515594042

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 85

Metadata

Authors
Radaelli, M., Moiola, L., Sangalli, F., Esposito, F., Barcella, V, Ferrè, L., Rodegher, M., Colombo, B., Fazio, R., Martinelli, V, & Comi, G.
Venue
Multiple Sclerosis Journal
Published
2015-07-21
Volume
22
Issue
4
Pages
511-519
ISSN
  • 1352-4585 (ISSN-L)
  • 1477-0970
OpenAlex
W2242473891
Cited by
85
References
3
FWCI
6.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. https://app.cochat.ai/papers/10.1177/1352458515594042
The paper
Radaelli, M., Moiola, L., Sangalli, F., Esposito, F., Barcella, V, Ferrè, L., Rodegher, M., Colombo, B., Fazio, R., Martinelli, V, & Comi, G. (2016). Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458515594042

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.